Real World Characterization of Women with Diagnosed Endometriosis Initiating Therapy with Elagolix Using a US Claims Database
Purpose Elagolix is an oral gonadotropin releasing hormone antagonist approved in the United States for the management of moderate to severe pain associated with endometriosis. We performed a real world evaluation of the demographic and clinical characteristics of women diagnosed with endometriosis who were initiating elagolix therapy in the United States. Patients and Methods This retrospective cohort database analysis included women 18 49 years of age with =1 pharmacy claim for elagolix between August 2018 and December 2019 from the Copyright (c) 2020 Truven Health Analytics LLC. All Rights Reserved. Women had continuous medical and pharmacy health plan enrollment during the baseline period (year immediately preceding the index date [date of earliest elagolix claim] and had =1 medical claim with endometriosis (International Classification of Diseases [ICD] 9/10 code [617.x and N80.x] on or before the index date. Baseline demographics, comorbidities, ICD code based endometriosis anatomic site, endometriosis related treatments, and pain symptoms were summarized descriptively. Results The study included 2083 patients with mean age at baseline of 33.2 8.1 years. Comorbidities most commonly recorded were non cancer, non endometriosis pain (59.5% including arthritis/joint pain (43.7% and back/neck pain (31.7% and mental disorder (40.7% including anxiety (32.7% The majority of endometriosis diagnosis codes recorded referred to unspecified location (52.3% and pelvic peritoneum (23.0% 61.0% of patients received a medical endometriosis related treatment in the baseline period, with the most common treatments being contraceptives (various routes of administration, 40.2% and progestins (31.7% Additionally, 35.4% of the patients received an endometriosis related surgery during baseline, with the most common being laparoscopy (33.2% of all patients) Opioids were used during the baseline period by 57.3% of the patients. For pain symptoms, 71.5% 30.4% and 19.3% of the patients had claims for pelvic pain, dysmenorrhea, and dyspareunia, respectively. Conclusion Endometriosis therapies were used by a significant proportion of patients with endometriosis in the year immediately preceding elagolix initiation.
ClinicoEconomics and outcomes research CEOR